Tapestry to invest $15 million in recycled leather brand Gen Phoenix
Tapestry's investment will bring its stake in Gen Phoenix to 9.9%. Tapestry said the partnership will bolster its efforts to attract younger Generation Z consumers - those born from 1997 to 2012 - who have an appetite for sustainable leather goods.
The companies' partnership began in 2022 with the launch of Coach's Gen-Z oriented Coachtopia line, which makes products designed with at least 50% recycled leather fibers from waste that are supplied by Gen Phoenix, according to its website.
Scott Roe, who is both chief financial and chief operating officer at Tapestry, said Coachtopia is a bellwether for younger consumers' spending habits.
'It's not that Coachtopia is so commercially massive, but it is helping us understand what's important to this really critical demographic,' he said.
Roe would not say how much Coachtopia accounts for in Tapestry's total earnings, only that it is 'relatively small.' Gen Phoenix estimates that its materials have an 80% lower carbon footprint than virgin leather.
The brands previously collaborated on an uncoated lining material that Coachtopia brought to market in under a year, said Elyse Winer, chief marketing officer at Gen Phoenix.
As part of the investment, Gen Phoenix, which sources waste materials from European tanneries and factories, will supply recycled leather to Tapestry for three years.
Gen Phoenix CEO John Kennedy said the company is eager to work with all of Tapestry's brands.
Roe said it remains to be seen how the recycled material could be used in other product lines.
"There's a lot of opportunities to redirect a lot of that waste stream,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
SOUTH SAN FRANCISCO, Calif., July 15, 2025--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH). "We are pleased that the FDA has lifted the partial clinical hold on zetomipzomib in AIH after their review of our comprehensive safety assessment of the zetomipzomib program," said Chris Kirk, PhD, CEO and co-founder of Kezar. "We continue to believe that zetomipzomib has the potential to positively transform the lives of patients living with AIH. We look forward to engaging with the FDA to align on the design of the next clinical trial of zetomipzomib in AIH." Although Kezar has suspended development of zetomipzomib in lupus nephritis (LN) to focus on AIH, the company met with the Independent Data Monitoring Committee (IDMC) for the previously terminated PALIZADE clinical trial to review the safety profile of zetomipzomib. The IDMC has provided Kezar with recommendations for conducting future clinical trials in LN. Based on this feedback and internal analysis of safety data across all clinical studies involving zetomipzomib, Kezar plans to respond to the FDA Division of Rheumatology and Transplant Medicine with a request to lift the clinical hold on zetomipzomib in LN. About Zetomipzomib Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from completed clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases. About Autoimmune Hepatitis Autoimmune hepatitis (AIH) is a rare chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage, severely impacting patients' physical health and quality of life. Lifelong maintenance therapy is required to avoid relapse and burdensome adverse effects. If left untreated, AIH can lead to cirrhosis, liver failure and hepatocellular carcinoma. In the United States, AIH affects approximately 100,000 individuals, with incidence rates increasing. The cause of this condition remains unclear, with females affected four times as often as males. Currently, standard of care treatment for AIH is chronic, immunosuppressive treatment with corticosteroids that frequently cause life-altering side effects, including diabetes, osteoporotic fractures and cataracts. There is a significant need for treatment regimens that reduce or remove the need for chronic immunosuppression from use of corticosteroids. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit and follow us on LinkedIn, Facebook, Twitter and Instagram. Cautionary Note on Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "can," "should," "expect," "believe," "potential," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing and outcome of regulatory submissions and interactions with the FDA, EMA or any other regulatory agencies with respect to zetomipzomib or Kezar's clinical trials, the initiation of an additional clinical trial of zetomipzomib in AIH, and expectations regarding the removal of the clinical hold of zetomipzomib in LN, and the likelihood of obtaining regulatory approval of zetomipzomib. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, difficulties enrolling and conducting our clinical trials, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Kezar's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. View source version on Contacts Investor and Media Contact:Gitanjali JainSenior Vice President, Investor Relations and External AffairsKezar Life Sciences, Melden Sie sich an, um Ihr Portfolio aufzurufen.
Washington Post
20 minutes ago
- Washington Post
Google partners with Youngkin and offers AI training courses to Virginia job seekers
RESTON, Va. — Republican Gov. Glenn Youngkin announced on Tuesday that Google will partner with his administration to provide free and low-cost artificial intelligence certification courses to Virginians as part of his office's ongoing effort to connect citizens to new jobs amid changes to the state's economy. The partnership, which he has described as an AI career launchpad, will provide Google-sponsored AI training courses for up to 10,000 Virginians at any given time, officials said at Google's office in the northern part of the state.
Vogue
20 minutes ago
- Vogue
5 Reasons Why the T-Shirt Dress Is Your Easiest Style Solution, Every Time
Wardrobe staples are aptly named for a reason—their staying power is earned through their versatility. Some of the pieces that reside under this umbrella are the lived-in blue jean (no matter the rise or wash currently trending), the white summer dress, and the T-shirt. But there is a style that blends the best of both worlds, and that is the T-shirt dress. Vogue's Favorite T-Shirt Dresses Casual in spirit yet easy to dress up, the T-shirt dress has all the markings of a warm-weather wardrobe hero. The ultimate chameleon, its simplicity is exactly what makes it so wearable—it's essentially a blank canvas ready to be painted a hundred different ways. On its own, it gives cool-girl, effortless vibes for errands, weekend mornings, or brunch. Throw on knee-high motorcycle boots, and you're in your Glastonbury era. Wear it with a basket bag and a heeled thong sandal, and it's giving off-duty supermodel. You can accessorize with a silk scarf tied around the waist, toss a shell-laden pendant around your neck, or belt it for an evening out. Because it blurs the line between pulled-together and laidback, it works for almost every setting. Luckily, there are plenty of T-shirt dresses to play with this season, from luxe styles found at The Row and Khaite to more attainable options from Leset and Cos. Either way, all you have to add are a few key accessories. Shop some of our favorite T-shirt dresses below, with a few outfit ideas on how to wear them right now. outfits, below. The White Knit With Summer's Most Wanted Accessories AYR's soft-knit white T-shirt dress pairs perfectly with croc-embossed flip-flops and Bembein's woven bag—perfect for retaining a sense of polish over a long weekend. The Striped Style With Fashion-Forward Accessories You've spent all day window shopping with friends, but dinner and drinks are on the agenda! What to wear when there are multiple plans on the calendar? Cos's easy striped T-shirt dress, Alaïa's mesh bag, and a silver pendant necklace from Agmes make for a winning combo. The Head-to-Toe Neutral Outfit While summer is all about color, monochrome looks are just what the mood calls for some days. Brown accents, in a pair of fisherman sandals and a unique basket bag, add just enough depth. Kule The Tee dress $178 KULE Hunting Season The Pendant tagua and leather necklace $275 NET-A-PORTER The Artful Drape With Playful Accessories Add whimsy and creative touches to your look with Presley Oldham's beaded and pearl bracelet, and Loewe's leather-trimmed raffia bag—fashionable ways to embrace summer's carefree attitude. The Classic Black Dress With a Scarf-Wrapped Waist This outfit is as simple, but as chic, as they come. To add detail back in, cinch a silk printed scarf around your waist. Ballet flats and a raffia bag complete the look. Shop More T-Shirt Dresses:
